CClinicalTrials.gg
CompletedNCT04774120Updated Mar 16, 2022

Relationship Between Bispectral Index, EEG Features, and Propofol Effect-site Concentration in Young and Elderly Patients.

An observational study in Electroencephalography, Aging and Propofol, sponsored by Pontificia Universidad Catolica de Chile. Completed at 1 site in Chile. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-16.

Sponsored by Pontificia Universidad Catolica de Chile · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The aim of this study is to describe the BIS values and electroencephalographic patterns during total intravenous anesthesia with propofol-remifentanyl, in patients from 18 to 85 years.

Read the detailed description

Propofol is an anesthetic drug regularly used in elderly patients requiring anesthesia. The electroencephalographic pattern recognized when propofol is administered is different from the pattern obtained in younger patients. Both groups present alpha and slow delta bands, but younger patients present more intense electroencephalographic bands than older patients (1). The correlation between BIS values and the power of electroencephalographic frequency bands during propofol-remifentanyl anesthesia has not been determined.

The investigators will describe the changes in BIS values and electroencephalographic patterns in young and elderly patients receiving propofol-remifentanyl anesthesia for elective surgery, at different propofol concentration levels. Formal characterization of the dynamic relationship between propofol concentrations at the effect site (Ce), spectral power, and BIS values may provide clinically relevant information to design propofol dose schemes in elderly patients.

The investigators will carry out a prospective observational clinical study at the Clinical Hospital of the Catholic University of Chile. 30 patients, aged 18-85 years, scheduled to undergo elective surgery will be recruited. Standard monitoring and 2 frontal EEG monitors will be installed: Sedline® and BIS®. The electroencephalographic signal from these monitors will be recorded simultaneously from anesthesia induction until extubation. Propofol will be started at a rate of 15-20 mg/kg/hr in patients >65 years and 20-25 mg/kg/hr in younger patients (\<65 years) until a suppression rate (SR) >1% appears in the BIS® EEG monitor. If the SR is not achieved, the infusion rate can be increased by 5 mg/kg/hr every 5 minutes until 25 mg/kg/hr in the elderly group and 30 mg/kg/hr in the younger group. When the SR appears, propofol infusion will be stopped. The induction phase will be considered completed at this point. Loss of response (LOR), defined as the timepoint when patients became unresponsive to verbal commands, soft shaking, and eyelash reflex, will be assessed every 30 seconds. When patients become apneic, positive pressure mask ventilation will be started gently at a rate of 10 breaths per minute. After induction of anesthesia, opioids and neuromuscular blocking drugs will be given to facilitate tracheal intubation. When BIS values increase to recommended hypnotic levels for surgery (40-60), the propofol infusion rate will be started again at half of the induction rate. This rate will be adjusted to maintain the alpha band present in the Sedline spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered and hidden from the attending anesthesiologist during the maintenance phase. After surgery ends, EEG monitoring will continue until the patient's extubation. One hour after extubation, the Brice questionnaire will be performed to detect intraoperative awakening. Propofol concentration will be estimated using the Schnider model.

02

Conditions studied

  • Electroencephalography
  • Aging
  • Propofol
  • Depth of Anesthesia

Keywords

  • electroencephalography
  • bispectral index
  • propofol
  • alpha band
  • aging
  • burst suppression
03

In context

Lead sponsor

Pontificia Universidad Catolica de Chile is the lead sponsor of 215 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Elderly patients scheduled for surgery are an understudied population. Incidence of postoperative delirium and other complications can be related to changes in cerebral dynamics under anesthesia, with effects observed even after the use of anesthetics agents.

Formal characterization of the dynamic relationship between propofol concentrations at the effect site (Ce), spectral power, and BIS values may provide clinically relevant information to design propofol dose schemes in young and elderly patients.

Inclusion criteria

  • Adult patients scheduled for elective surgery requiring general anesthesia.
  • American Society of Anesthesiology (ASA) Score I or II

Exclusion criteria

Exclusion Criteria:

  • Patients with neurological diseases or history of cognitive impairment.
  • Requiring the use of two or more drugs affecting Central nervous system
  • History of drugs or alcohol abuse
  • Body mass index over 35 kg/m\^2
  • Propofol allergy
  • Cardiac congestive failure
  • History of coronary syndrome
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Young Patients (Patients aged 18 to 65 years.)

    Propofol infusion rate will be started at 20-25 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.

    Drug: Propofol

  • Elderly patients (Patients aged 65 to 85 years. )

    Propofol infusion rate will be started at 15-20 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.

    Drug: Propofol

Interventions

  • DrugPropofol

    Propofol will be started at a rate of 15-20 mg/kg/hr in patients \>65 years and 20-25 mg/kg/hr in younger patients (\<65 years) until a suppression rate (SR) is achieved. If not, can be increased by 5 mg/kg/hr every 5 minutes up to 25 mg/kg/hr in the elderly group and 30 mg/kg/hr in the younger group or after 15 minutes have passed. When the SR appears, propofol infusion will be stopped. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.

    Also known as: Diprivan, Propoven

06

What researchers measure

Primary outcomes

  1. BIS values at which EEG patterns appears during induction of anesthesia with propofol.

    BIS values correlated to specific EEG patterns (frequency bands, complexity measures and burst suppression)

    Time frame: From induction of anesthesia until suppression rate appears, an average of 15 minutes.

Secondary outcomes

  1. Propofol effect-site concentration (µg/ml) required to observe specific EEG patterns

    Propofol effect-site concentrations achieved at the time that specific EEG patterns appear (frequency bands power, complexity measures and burst suppression).

    Time frame: From induction of anesthesia until loss of consciousness, an average of 15 minutes.

  2. Propofol effect-site concentration (µg/ml) required to achieve loss of consciousness

    Propofol effect-site concentration (µg/ml) at the moment of loss of consciousness

    Time frame: From Induction of anesthesia until suppression rate appears, an average of 15 minutes.

  3. BIS values at loss of consciousness

    BIS values at the moment of loss of consciousness

    Time frame: From Induction of anesthesia until suppression rate appears, an average of 15 minutes.

  4. Percentage of time with BIS values between 40-60 and out of this range.

    Percentage of time that BIS values are between 40-60 and out of this range.

    Time frame: From induction of anesthesia until patient's extubation, an average of 90 minutes.

  5. Time to achieve loss of consciousness

    Time (minutes) to achieve loss of consciousness.

    Time frame: From Induction of anesthesia until loss of consciousness, an average of 10 minutes.

  6. Time to achieve loss suppression rate >1% in BIS monitor.

    Time (minutes) to achieve loss suppression rate \>1% in BIS monitor.

    Time frame: From Induction of anesthesia until suppression rate appears, an average of 15 minutes.

07

Study locations

1 site
  • Division de Anestesia - Pontificia Universidad Catolica de Chile
    Santiago, Metropolitana 8330024, Chile
08

References and documents

Publications

  • Purdon PL, Pavone KJ, Akeju O, Smith AC, Sampson AL, Lee J, Zhou DW, Solt K, Brown EN. The Ageing Brain: Age-dependent changes in the electroencephalogram during propofol and sevoflurane general anaesthesia. Br J Anaesth. 2015 Jul;115 Suppl 1(Suppl 1):i46-i57. doi: 10.1093/bja/aev213. PubMed 26174300 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04774120
Lead sponsor
Pontificia Universidad Catolica de Chile
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Dec 11, 2020
Primary completion
Mar 30, 2021
Completion
May 30, 2021
Last update
Mar 16, 2022

Study contacts

Daniela Muñoz, MD
principal investigator · Pontificia Universidad Catolica de Chile

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion